Atai Beckley N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.320
-0.080 (-1.82%)
At close: Dec 5, 2025, 4:00 PM EST
4.250
-0.070 (-1.62%)
After-hours: Dec 5, 2025, 7:19 PM EST
Atai Beckley Revenue
Atai Beckley had revenue of $749.00K in the quarter ending September 30, 2025, with 1,772.50% growth. This brings the company's revenue in the last twelve months to $3.02M, up 811.78% year-over-year. In the year 2024, Atai Beckley had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$3.02M
Revenue Growth
+811.78%
P/S Ratio
268.97
Revenue / Employee
$55,889
Employees
54
Market Cap
1.57B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATAI News
- 16 days ago - Enhanced Fortifies Executive Leadership Team & Board of Directors - PRNewsWire
- 25 days ago - Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript - Seeking Alpha
- 6 weeks ago - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - GlobeNewsWire
- 6 weeks ago - Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics - Seeking Alpha
- 7 weeks ago - Why Atai Life Sciences Stock Was So Lively This Week - The Motley Fool
- 7 weeks ago - atai Life Sciences Announces Pricing of Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - atai Life Sciences Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression - GlobeNewsWire